comparemela.com
Home
Live Updates
What happens when a $2 million gene therapy is not enough :
What happens when a $2 million gene therapy is not enough :
What happens when a $2 million gene therapy is not enough
(This Aug. 12 story has been corrected to state that ICER's final analysis was that Zolgensma was cost effective at a price of $1.1 million to $1.9
Related Keywords
Kazakhstan ,
Columbus ,
Ohio ,
United States ,
Switzerland ,
Berwyn ,
Illinois ,
Chicago ,
Russia ,
Virginia ,
Lebanon ,
Americans ,
Deena Beasley ,
Roger Hajjar ,
Elizabeth Kutschke ,
Roche Evrysdi ,
Sitra Tauscher Wisniewski ,
Amanda Cook ,
Eric Cox ,
Sree Chaguturu ,
Sara Ledwith ,
Vasant Narasimhan ,
Maha Radhakrishnan ,
Steven Pearson ,
Stacie Dusetzina ,
Ben Kutschke ,
Caroline Humer ,
Russell Butterfield ,
Jerry Mendell ,
Aetna ,
Brigham Gene Cell Therapy Institute ,
Novartis ,
University Of Utah Health ,
Institute For Human Data Science ,
Institute For Clinical ,
Unitedhealth Group ,
Nashville Vanderbilt University School Of Medicine ,
Drug Administration ,
Reuters ,
Baby Ben Kutschke ,
Human Data ,
Novartis Gene ,
Mass General Brigham Gene ,
Cell Therapy ,
Vanderbilt University School ,
Economic Review ,
Chief Medical Officer Maha Radhakrishnan ,
Nationwide Children ,
Utah Health ,
Intermountain Primary Children ,